|
|
Post by gerald on Apr 9, 2019 12:09:30 GMT -5
I have included a link to the full report in PDF down below.
However, it appears in trials that Riociguat revrses Pulmonary Hypertension to
normal in Mice. It appears that there have been small human trials as well and
these were successful.
--------------------------- Right ventricular systolic pressure (RVSP) was increased after 8 months of smoke exposure as compared to controls (Figure 1a: second group “smoke exposure 8 months”, black bar) and did not changeupon subsequent exposure to room air for 3 months(Figure 1a: 4thgroup “smoke exposure 8 months plus 3 months placebo”, dark grey bar). Riociguat in either concentration (3 or 10 mg/kg/d) decreased RVSP to the level of healthy lungs(Figure 1a: 5thand 6thgroup “smoke exposure 8 months plus 3 months 3 or 10 mg riociguat”
----------------------------------------------
Riociguat for treatment of pulmonary hypertension in COPD
|
|
